CYBB and COVID-19: Recently, it has been shown that patients with COVID-19 have significant higher markers of oxidative stress (such as soluble Nox2-derived peptide and hydrogen peroxide) and inflammation (TNF-α and IL-6), while, conversely, flow-mediated dilation, hydrogen peroxide breakdown activity and nitric oxide (NO) bioavailability were shown to be significantly lower [122].